Datapoint: Novartis Reportedly Mulls Sandoz Spinoff

Novartis is reportedly considering spinning off its $25 billion generics unit, Sandoz, according to a June 30 report in Bloomberg. Novartis has been conducting a strategic review of Sandoz since last fall, and plans to share results by the end of this year. Novartis saw $9.2 billion in generic drug sales in 2021, and sales of $9.4 billion are projected for 2022. Its top-selling retail generics in the U.S. are omeprazole, tamsulosin hydrochloride and latanoprost.

From Evaluate Pharma

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 5

Datapoint: EmblemHealth Subsidiary Pulls Out of Connecticut Small Group Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today